Drug intelligence / Profile preview

CV09070101

Development stage
Discontinued
Lead developer
BioNTech
Modality
mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular, Parenteral, Injection
01

Overview

CV09070101 is an investigational mRNA-based cancer vaccine developed for the treatment of squamous non-small cell lung cancer (sqNSCLC). It is designed as a personalized immunotherapy to stimulate the immune system to recognize and target cancer-specific antigens. The vaccine is under development by CureVac and myNEO and acts as an immunostimulant, falling under the categories of antineoplastics, cancer vaccines, immunotherapies, and RNA vaccines. Development is in preclinical and very early clinical phases, with studies evaluating its safety and efficacy in combination with pembrolizumab and chemotherapy in advanced, inoperable, or metastatic sqNSCLC[1][3][5][9].

Other names
CV09070101 mRNA vaccineCV-09070101 mRNA vaccineCV 09070101 mRNA vaccine

Beyond the preview

Go deeper on CV09070101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CV09070101.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call